Johnson & Johnson (JNJ)
| Market Cap | 345.07B |
| Revenue (ttm) | 87.70B |
| Net Income (ttm) | 14.68B |
| Shares Out | 2.41B |
| EPS (ttm) | 6.04 |
| PE Ratio | 23.72 |
| Forward PE | 14.17 |
| Dividend | $4.96 (3.46%) |
| Ex-Dividend Date | Feb 18, 2025 |
| Volume | 2,052,194 |
| Open | 144.50 |
| Previous Close | 144.47 |
| Day's Range | 142.92 - 144.58 |
| 52-Week Range | 140.68 - 168.85 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 173.85 (+21.3%) |
| Earnings Date | Jan 22, 2025 |
About JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lu... [Read more]
Financial Performance
In 2023, Johnson & Johnson's revenue was $85.16 billion, an increase of 6.46% compared to the previous year's $79.99 billion. Earnings were $35.15 billion, an increase of 95.94%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $173.85, which is an increase of 21.30% from the latest price.
News
Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). In...
7 Blue Chip Dividend Stocks I Used To Build My First $100K Portfolio
Building good financial habits and avoiding debt traps is the hardest part of accumulating your first $100K. Invest in companies with growing earnings, consistent dividends, low debt, and an establish...
Healthcare sector poised for rebound in 2025
The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK).
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular T...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Johnson & Johnson (JNJ) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2024 12:00 PM ET Company Participants Joaquin Duato - Chairman & CEO Conference Call Participants Chris Schott -...
Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal
Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.
Dean Omar Branham Shirley's Partners Named to List of 500 Leading Lawyers in America
DALLAS--(BUSINESS WIRE)--Dean Omar Branham Shirley, a plaintiff firm known for aggressively advocating for the rights of consumers, announced that name partners Jessica Dean and Trey Branham have been...
Drugmakers rush to sign deals on first day of industry conference
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
On Monday, Johnson & Johnson JNJ agreed to acquire Intra-Cellular Therapies Inc. ITCI for $132.00 per share in cash for a total equity value of approximately $14.6 billion.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Johnson & Johnson (JNJ) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). In...
Johnson & Johnson makes $15 billion bet on mental-health drugs
Pharma giant Johnson & Johnson is buying Intra-Cellular Therapies, eying sales growth above analysts' expectations through 2029.
J&J to buy Intra-Cellular Therapies for $14.6 billion
Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in the market for neurological disorder treatments.
J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports
Johnson & Johnson is exploring a bid to acquire Intra-Cellular Therapies Inc , a biopharmaceutical company, Bloomberg News reported on Sunday citing people familiar with the matter.
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). In...
Johnson & Johnson Could Serve As High-Yield Bond Alternative
Johnson & Johnson remains a "Buy" for its stability and consistent dividends, despite short-term price fluctuations and modest growth expectations. Q3 2024 results showed a 5.2% sales increase but a s...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Johnson & Johnson (JNJ) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). In...
What To Expect From JNJ Stock In 2025?
Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like E...
Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis
Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positive...
J&J pauses rollout of heart device in the US to investigate stroke risk
Johnson & Johnson said on Wednesday that it has temporarily paused the rollout of its Varipulse heart device in the United States, citing an abundance of caution as the company investigates four repor...
Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer
The latest dividend declarations, combined with stock price movements, have pushed PFE's yield to be almost twice as JNJ's. But I want to caution you to look beyond yield (and P/E too) and examine oth...
Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track designations reinforce J&J's com...
Johnson & Johnson: A Potential Beneficiary Of A Great Rotation
Johnson & Johnson's stagnant price and bond-like behavior make it an income investment, but a market shift could boost its appeal in 2025. Value stocks, including JNJ, may gain favor as growth stocks'...
Buy 1 January S&P 500 Dividend Aristocrat Out Of 38 'Safer'
**Investment Thesis:** January's top-yielding Aristocrats include Franklin Resources, Realty Income, Amcor, Kenvue, and Hormel, offering dividends from $1K investments exceeding single share prices. *...
Johnson & Johnson: I'm Saying Yes To This Mess
JNJ's long-term buy rating is based on its blue-chip pedigree, profitability, and diverse revenue lines, despite recent price stagnation and litigation risks. I emphasize adapting to market conditions...